FDMT实时信号 | 通过Getagraph.com最大化利润

出售 106334 min ago

@ $27.97

发出时间: 15 Feb 2024 @ 04:13

回报率: -16.88%

上一信号: Feb 15 - 02:43

上一信号: 购买

回报率: 2.04 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	317 415
平均成交量	1.21M
市值	1.19B
EPS	$0 ( 2024-03-20 )
下一个收益日期	( $-0.730 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.01
ATR14	$0.0280 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-16	Bizily Scott	Sell	1 250	Stock Option (Right To Buy)
2024-04-16	Bizily Scott	Sell	500	Stock Option (Right To Buy)
2024-04-16	Bizily Scott	Buy	1 250	Common Stock
2024-04-16	Bizily Scott	Buy	500	Common Stock
2024-04-16	Bizily Scott	Sell	1 750	Common Stock

INSIDER POWER
31.08
Last 99 transactions
Buy: 3 571 023 \| Sell: 1 811 773

音量相关性

長: -0.14 (neutral)

短: 0.80 (moderate)

Signal:(50.646) Neutral

4D Molecular 相关性

10 最正相关
AFYA	0.848
RMCF	0.839
GOEV	0.826
NTCT	0.826
SLM	0.821
IMGN	0.818
TRMK	0.817
NDAQ	0.817
PRCT	0.816
LSXMA	0.816

10 最负相关
ISDX	-0.838
ZIONP	-0.827
TRHC	-0.826
NVSAU	-0.823
KSICU	-0.822
IOAC	-0.821
GRBK	-0.815
XFIN	-0.813
VRIG	-0.812
BRIVU	-0.81

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

4D Molecular 相关性 - 货币/商品

0.09
( neutral )

0.05
( neutral )

0.00
( neutral )

0.48
( neutral )

-0.08
( neutral )

0.07
( neutral )

4D Molecular 财务报表

Annual	2023
营收:	$20.72M
毛利润:	$14.97M (72.26 %)
EPS:	$-2.58

FY	2023
营收:	$20.72M
毛利润:	$14.97M (72.26 %)
EPS:	$-2.58

FY	2022
营收:	$3.13M
毛利润:	$-751 000 (-24.00 %)
EPS:	$-3.12

FY	2021
营收:	$18.04M
毛利润:	$0.00 (0.00 %)
EPS:	$-11.09

Financial Reports:

No articles found.

4D Molecular

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.